ArticleClinical medicine insights. Endocrinology and diabetes2026
Secondary Adrenocortical Insufficiency in Liver Cancer Patient After Treatment With Cadonilimab: A Case Report.
Article in Clinical medicine insights. Endocrinology and diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) offer important clinical benefits in antitumor therapy. However, they may cause potential and unpredictable immune-related adverse events (irAEs) due to the non-specific immunity activation. Although adrenocortical insufficiency (AI) is a rare irAE, rapid identification and treatment can help patients avoid life-threatening cortisol crises. We describe the case of a 60-year-old Chinese male patient with liver cancer who developed intractable hyponatremia, fatigue, and loss of appetite three months after completing treatment with cadonilimab. Intravenous rehydration and symptomatic treatment were ineffective. The diagnosis of ICI-induced secondary AI was confirmed after refinement of cortisol levels and adrenocorticotropic hormone (ACTH). Additionally, mild subclinical hypothyroidism was identified as a concurrent endocrine finding. Electrolyte disturbances and general malaise improved markedly after oral administration of exogenous cortisol hormone. This case supports existing evidence regarding ICI-related secondary AI and highlights the importance of timely endocrine evaluation in patients with persistent hyponatremia and non-specific systemic symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.